author-photo

Sean Landrette

Yale University

28

Papers

641

Citations

Citation Trend

Filter By

Papers (19) Sort By

Journal Conference Others

Results of a completed phase I study of LAM-002 (apilimod dimesylate), a first-in-class phosphatidylinositol-3-phosphate 5 kinase (PIKfyve) inhibitor, administered as monotherapy or with rituximab or atezolizumab to patients with previously treated follicular lymphoma or other B-cell cancers.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Disease

2019 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Phase 1 Clinical Safety, Pharmacokinetics (PK), and Activity of Apilimod Dimesylate (LAM-002A), a First-in-Class Inhibitor of Phosphatidylinositol-3-Phosphate 5-Kinase (PIKfyve), in Patients with Relapsed or Refractory B-Cell Malignancies

2017 Blood
Show All
- Source
- Cite
- Save
Citations (8)
B-cell non-Hodgkin lymphoma: Selective vulnerability to PIKFYVE inhibition

2017 Autophagy
Show All
- Source
- Cite
- Save
Citations (9)
Métabolites actifs d'apilimod et leurs utilisations

2016
Show All
- Source
- Cite
- Save
Citations (0)
Compositions antivirales contenant des inhibiteurs de pikfyve et leur utilisation

2016
Show All
- Source
- Cite
- Save
Citations (0)
Méthodes de traitement du cancer avec de d'apilimod

2016
Show All
- Source
- Cite
- Save
Citations (0)
Compositions d'apilimod et procédés pour les utiliser

2015
Show All
- Source
- Cite
- Save
Citations (0)
Apilimod pour une utilisation dans le traitement du cancer colorectal

2015
Show All
- Source
- Cite
- Save
Citations (0)
Apilimod destiné à être utilisé dans le traitement du mélanome

2015
Show All
- Source
- Cite
- Save
Citations (0)